Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $407.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 5.36% year-over-year to $407.1 million; the TTM figure through Mar 2026 stood at $407.1 million (up 5.36% YoY), while the FY2025 annual figure was $428.3 million, up 17.99% from the prior year.
• Other Accumulated Expenses was $407.1 million for Q1 2026 at Vertex Pharmaceuticals, down from $428.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $648.6 million in Q1 2024 to a low of $218.0 million in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $376.6 million across 5 years, with a median of $377.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 72.04% in 2024, then slumped 40.43% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $311.5 million in 2022, then jumped by 69.25% to $527.2 million in 2023, then tumbled by 31.15% to $363.0 million in 2024, then climbed by 17.99% to $428.3 million in 2025, then decreased by 4.95% to $407.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $407.1 million (Q1 2026), $428.3 million (Q4 2025), and $441.5 million (Q3 2025), per Business Quant data.